Table of Contents

1. Understanding COVID-19 IgG/IgM Tests
2. Mechanism of IgG/IgM Tests
3. Interpretation of Results
4. Company Solutions
5. References

Understanding COVID-19 IgG/IgM Tests

COVID-19 IgG/IgM tests are serological tests used to detect the presence of antibodies against SARS-CoV-2, the virus responsible for COVID-19. These tests are crucial for understanding immune response, epidemiological studies, and guiding public health policies. IgG and IgM are two types of immunoglobulins that are predominantly produced in response to viral infections.

Mechanism of IgG/IgM Tests

The IgG/IgM test is an immunoassay used to qualitatively assess COVID-19-specific IgG and IgM antibodies in human serum, plasma, or whole blood samples.

• IgM Antibodies: Typically appear within 7 to 10 days after exposure to the virus. Their presence suggests a recent infection.
• IgG Antibodies: Usually develop 10 to 14 days post-infection and may indicate a later stage of infection or past exposure.

The test utilizes recombinant SARS-CoV-2 antigens to capture these antibodies in the sample. The presence of a colored line in the test result window corresponds to the presence of IgG or IgM antibodies.

Interpretation of Results

The results from COVID-19 IgG/IgM tests can be interpreted as follows:

• IgM Positive, IgG Negative: Indicative of a current or recent infection.
• IgM Positive, IgG Positive: Suggests active infection or recent conversion.
• IgM Negative, IgG Positive: Likely past infection with developed immunity.
• IgM Negative, IgG Negative: No evidence of infection. It is advisable to follow up with an RT-PCR test if symptoms persist.

Sensitivity and specificity are critical performance indicators for these tests. According to recent studies, IgM tests have a sensitivity of approximately 85% and specificity of 96%, while IgG tests show sensitivity of 90% and specificity of 98%.

Company Solutions

Various companies have developed IgG/IgM tests, offering diverse solutions to cater to global demand. Below are some leading providers:

• Abbott Laboratories: Known for its Panbio COVID-19 IgG/IgM Rapid Test Device, which is designed for high throughput with sensitivity rates of 91% for IgG and 88% for IgM.
• Roche Diagnostics: Offers the Elecsys Anti-SARS-CoV-2 serology test with sensitivity and specificity over 99%.
• Bio-Rad Laboratories: Provides the Platelia SARS-CoV-2 Total Ab test, focusing on both IgA and IgM/IgG with demonstrated sensitivity of 98%.

References

1. World Health Organization. (2020). Immunity Passports in the context of COVID-19.
2. Centers for Disease Control and Prevention. (2021). Interim Guidelines for COVID-19 Antibody Testing.
3. Abbott Laboratories. (2021). COVID-19 Rapid Test Solutions. [Web page]
4. Roche Diagnostics. (2021). Elecsys Anti-SARS-CoV-2 Product Documentation. [Web page]
5. Bio-Rad Laboratories. (2021). Platelia SARS-CoV-2 Test Information. [Web page]